Abstract

microRNAs are short noncoding RNAs that regulate protein expression posttranscriptionally. We previously showed that miR-155 promotes effector CD8+ T-cell responses. However, little is known about the regulation of miR-155 expression. Here, we report that antigen affinity and dose determine miR-155 expression in CD8+ T cells. In B16 tumors expressing a low-affinity antigen ligand, tumor-specific infiltrating CD8+ T cells showed variable miR-155 expression, whereby high miR-155 expression was associated with more cytokine-producing cells and tumor control. Moreover, anti-PD-1 treatment led to both increased miR-155 expression and tumor control by specific CD8+ T cells. In addition, miR-155 overexpression enhanced exhausted CD8+ T-cell persistence in the LCMV cl13 chronic viral infection model. In agreement with these observations in mouse models, miR-155 expression in human effector memory CD8+ T cells positively correlated with their frequencies in tumor-infiltrated lymph nodes of melanoma patients. Low miR-155 target gene signature in tumors was associated with prolonged overall survival in melanoma patients. Altogether, these results raise the possibility that high miR-155 expression in CD8+ tumor-infiltrating T cells may be a surrogate marker of the relative potency of in situ antigen-specific CD8+ T-cell responses.

Highlights

  • High numbers of tumor-infiltrating memory CD8þ T cells are associated with better clinical outcome in different types of human cancers [1]

  • We previously reported that miR-155 expression is upregulated in effector memory (EM) compared with na€ve (N) CD8þ T cells from the blood of healthy donors (HD) [7]. miR-155 expression in peripheral blood (PB) CD8þ T-cell subsets from melanoma patients was similar to those of HDs, whereby EM and CD45RAþ EM (EMRA) CD8þ T cells showed increased miR-155 expression compared with N and central memory (CM) CD8þ T cells (Fig. 4A)

  • We found that miR-155 expression in CD8þ T cells reflects the strength of in situ antigen stimulation, independent of the inflammatory environment

Read more

Summary

Introduction

High numbers of tumor-infiltrating memory CD8þ T cells are associated with better clinical outcome in different types of human cancers [1]. Tumors manage to evade immune control through multiple mechanisms [2]. Efforts are being made to develop new cancer immunotherapies aiming at boosting the antitumor immune response. Reinfusion of ex vivo–expanded autologous tumor-reactive T cells has shown encouraging results in malignant melanoma patients [3, 4]. Trafficking, survival, and persistence of reinfused T cells need to be optimized, and genetic engineering of T cells is an approach currently explored to improve T-cell qualities. Genetic manipulation of specific microRNAs may allow improvement of T-cell fitness [5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call